About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

By: via Business Wire

NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets for the treatment of moderate to severe atopic dermatitis (AD)

Combined single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a/1b clinical study to be conducted in collaboration with Asia-regional partner Kaken Pharmaceutical

Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).

The first subject dosing marks the beginning of a combined single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a/1b clinical study, conducted in collaboration with Numab’s Asia-regional partner Kaken Pharmaceutical. The study will enroll non-Asian and Japanese healthy volunteers in the SAD sub-study and moderate-to-severe AD patients in the MAD sub-study. The SAD sub-study is currently enrolling.

“It is an exciting milestone for Numab to initiate this study of NM26-2198, our first product candidate focused on the treatment of inflammatory conditions and our second multi-specific antibody therapeutic to advance to the clinic,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics. “Our team has leveraged our technology platforms to develop this novel, first-in-class bi-specific antibody therapeutic that is designed to deliver an earlier onset of efficacy and larger effect size than current standard of care in atopic dermatitis and other inflammatory conditions.”

AD is an inflammatory skin condition which is characterized by a vicious cycle of skin inflammation that causes itching and scratching, which in turn exacerbates damage to the skin barrier and inflammation and furthers itching, resulting in the characteristic skin lesions for which AD is known. In the United States and the European Union markets, approximately 17-26 million patients suffer from moderate-to-severe AD.

NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block itch and inflammation, with the aim of improving quality of life relative to current standard of care treatment. NM26-2198 inhibits three key pathways involved in disease pathogenesis of AD. While standard of care blocks IL-4 and IL-13, NM26-2198 blocks IL-31 in addition, thereby specifically targeting the neuroinflammatory pathway that causes itch.

“Based on its unique mechanism of action, we believe that NM26-2198 has the potential to deliver faster and more pronounced relief from itch than the current standard of care AD treatment,” said Peter Lichtlen, M.D., Ph.D., Founder and Chief Medical Officer of Numab Therapeutics. “This effect would be notable for people suffering with AD, as we know itch is a major factor of disease burden that negatively impacts quality of life and sleep. Faster onset and deepened suppression of itch is also expected to result in a more pronounced effect on AD lesions.” Dr. Lichtlen continued, “We look forward to progressing this Phase 1a/1b clinical trial. It has been a great privilege to develop this novel molecule with our world-class network of leading clinical experts in the AD space and to be supported by our Japanese partner Kaken Pharmaceutical on this path.”

About NM26-2198

NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis (AD). The antibody therapeutic is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Numab is developing this molecule together with its Japanese partner Kaken Pharmaceutical. While Kaken owns commercial rights to certain Asian territories including Japan, Numab owns the rights to the rest of the world, including Europe and the United States of America.

About Numab Therapeutics

Numab Therapeutics is an immunology and oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit www.numab.com.

About Kaken Pharmaceutical

Kaken is an R&D driven pharmaceutical company, established in 1948, and its corporate philosophy is to help improve the quality of life of patients by serving as many people as possible to return smiles of happiness to their faces, through supplying superior pharmaceuticals. Recently, Kaken has increased its presence in dermatology and orthopedics, and Clenafin, a drug discovered in-house and first topical onychomycosis treatment in Japan, continues to grow as a global product. For more information, please visit https://www.kaken.co.jp/english/.

Contacts

More News

View More
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Why Wall Street Is Betting Billions on Oklo's Nuclear Vision
Via MarketBeat
Topics Artificial Intelligence
Tickers LBRT LEU OKLO VRT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.